Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers
Open Access
- 15 January 2011
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 11 (2) , 263-276
Abstract
The receptor tyrosine kinase ErbB2 is overexpressed in up to a third of breast cancers, allowing targeted therapy with ErbB2-directed humanized antibodies such as Trastuzumab. Concurrent targeting ...Keywords
This publication has 57 references indexed in Scilit:
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative ApoptosisCancer Cell, 2008
- Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneProceedings of the National Academy of Sciences, 2008
- Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to TrastuzumabMolecular and Cellular Biology, 2008
- Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataBlood, 2008
- Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted MoleculeMolecular Biology of the Cell, 2008
- Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in MelanomaClinical Cancer Research, 2007
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001